AMENDMENT NO. 1 TO THE FEBRUARY 8, 2018 PLATFORM AGREEMENT BY AND AMONG PIERIS PHARMACEUTICALS, INC. AND PIERIS PHARMACEUTICALS GMBH AND SEATTLE GENETICS, INC. This amendment to the Non-Exclusive Anticalin® Platform Technology License Agreement (the...Non-Exclusive Anticalin® Platform Technology License Agreement • August 10th, 2020 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
AMENDMENT NO. 1 TO THE FEBRUARY 8, 2018 LICENSE AND COLLABORATION BY AND AMONG PIERIS PHARMACEUTICALS, INC. AND PIERIS PHARMACEUTICALS GMBH AND SEATTLE GENETICS, INC. This amendment to the license and collaboration agreement (the “Amendment No. 1”) is...License and Collaboration Agreement • August 10th, 2020 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
